STAAR Surgical Company (NASDAQ:STAA) was founded in 1982 and is headquartered in Monrovia, California, USA, with 475 full-time employees. It is a medical device and supplies company, together with its subsidiaries, designing, developing, manufacturing, distributing and selling Implantable contact lenses, and delivery systems for delivering lenses to the eye.
STAAR Surgical Company (STAA):
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures and sells implantable lenses for the eye and laser systems for implanting lenses into the eye. STAAR Surgical provides:
1. Visian-Implantable contact lens (ICL), to treat vision disorders, such as myopia, hyperopia, astigmatism, and presbyopia; Implantable contact lens (ICL) for hyperopia, to treat hyperopia.
2. Provide minimally invasive intraocular lenses (IOL), including folding intraocular lenses, used for minimally invasive cataract surgery; aspheric intraocular lenses, which can present clearer images than traditional spherical lenses; nanoFLEX intraocular lenses, a single piece Aspheric contact lenses; toric intraocular lenses, preloaded syringes for cataract patients and cataract surgery are provided.
3. In addition, STAAR Surgical Company sells surgical products, other related instruments and equipment, syringe components and manufactures AquaFlow equipment for the treatment of glaucoma.
STAAR Surgical Company sells its products to medical care companies under the brands STAAR®, EVO Visian ICL, Evolution in Visual Freedom, Visian, Collamer, CentraFLOW, AquaPORT, nanoFLEX, nanoPOINT and Afinity (trademarks), including surgical centers, hospitals, and managed care Service providers, medical institutions, collective procurement organizations and government agencies.
STAAR Surgical Company sells products directly through its sales representatives in the United States, Japan, Spain, Germany, Canada, the United Kingdom and Singapore, and sells products through independent distributors in approximately 75 countries.
STAAR Surgical Company (STAA) History:
STAAR® was developed for cataract surgery, patented and licensed for the first folding intraocular lens (IOL). For the first time, a foldable intraocular lens made of a bendable material allows surgeons to replace the natural lens of cataract patients with minimally invasive surgery. Foldable intraocular lenses have become the standard care for cataract surgery worldwide. In 1991, STAAR introduced the first contact lens made of silicone.
In 1996, STAAR began selling VisianICL® outside the United States. ICL made of STAAR’s proprietary biocompatible Collamer® lens material is implanted behind the iris and in front of the patient’s natural lens to treat refractive errors such as myopia, hyperopia and astigmatism.
ICL obtained the CE certification in 1997, allowing it to be sold in countries that require the EU CE mark, and was approved by the US FDA for the treatment of myopia in December 2005.
STAAR sells EVO Visian ICL and Visian ICL series contact lenses in more than 60 countries and has been used by more than 800,000 customers worldwide.